Anti-CD123 antibody and application thereof

An antibody and antigen technology, applied in the field of immunology, can solve the problems of poor specificity and low affinity of CD123 antibody, and achieve the effect of strong binding specificity
CN112851807AActive Publication Date: 2021-05-28INST OF HEMATOLOGY & BLOOD DISEASES HOSPITAL CHINESE ACADEMY OF MEDICAL SCI & PEKING UNION MEDICAL COLLEGE +1
3 Cites 4 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
INST OF HEMATOLOGY & BLOOD DISEASES HOSPITAL CHINESE ACADEMY OF MEDICAL SCI & PEKING UNION MEDICAL COLLEGE
Publication Date
2021-05-28

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses an antibody specifically binding to CD123. The antibody comprises: a) CDR1, CDR2 and CDR3 regions of a heavy-chain variable region shown as SEQ ID No. 1 to 3 or regions 80% or more homogeneous with the CDR1, CDR2 and CDR3 regions; or b) CDR1, CDR2 and CDR3 regions of a heavy-chain variable region shown as SEQ ID No. 4 to 6 or regions 80% or more homogeneous with the CDR1, CDR2 and CDR3 regions; or c) CDR1, CDR2 and CDR3 regions of a heavy-chain variable region shown as SEQ ID No. 7 to 9 or regions 80% or more homogeneous with the CDR1, CDR2 and CDR3 regions. The monoclonal antibody can be used for detecting cells expressing CD123, and can also be applied to tumor immunotherapy independently or be applied to tumor immunotherapy in combination with other methods; that is, the monoclonal antibody can be effectively applied to preparation of drugs for treating tumors, infectious diseases and autoimmune diseases, resisting immunological rejection and the like.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The present invention relates to the field of immunology, more specifically, the present invention relates to anti-CD123 antibody and application thereof. Background technique

[0002] LSCs are the first cancer stem cells confirmed by Lapidot et al. It has similar unlimited proliferation and self-renewal capabilities to normal hematopoietic stem cells, most of them are in the quiescent phase, have self-protection mechanisms and survive in a highly protective microenvironment. Being able to escape the killing of conventional chemotherapy drugs, the persistence of LSCs is considered to be the root cause of leukemia occurrence, relapse, and drug resistance. Effective removal of LSCs has become an important goal of leukemia treatment.

[0003] In addition to having the same surface antigen phenotype as normal hematopoietic stem cells, AML HSCs (CD34 + , CD38 - , CD71 - 、HLA - DR - ), there are some self-specific surface antigen phenotypes (CD90 - / CD...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More